PL2475645T3 - 5-(3,4-dichlorofenylo)-n-(2-hydroksycykloheksylo)-6-(2,2,2- trifluoroetoksy)nikotynoamid i jego sole jako środki zwiększające poziom cholesterolu hdl - Google Patents
5-(3,4-dichlorofenylo)-n-(2-hydroksycykloheksylo)-6-(2,2,2- trifluoroetoksy)nikotynoamid i jego sole jako środki zwiększające poziom cholesterolu hdlInfo
- Publication number
- PL2475645T3 PL2475645T3 PL10749873T PL10749873T PL2475645T3 PL 2475645 T3 PL2475645 T3 PL 2475645T3 PL 10749873 T PL10749873 T PL 10749873T PL 10749873 T PL10749873 T PL 10749873T PL 2475645 T3 PL2475645 T3 PL 2475645T3
- Authority
- PL
- Poland
- Prior art keywords
- nicotinamide
- trifluoro
- dichloro
- ethoxy
- cyclohexyl
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 239000004131 EU approved raising agent Substances 0.000 title 1
- 235000012000 cholesterol Nutrition 0.000 title 1
- 235000010855 food raising agent Nutrition 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170097 | 2009-09-11 | ||
| PCT/EP2010/063136 WO2011029827A1 (en) | 2009-09-11 | 2010-09-08 | 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents |
| EP10749873.5A EP2475645B1 (en) | 2009-09-11 | 2010-09-08 | 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2475645T3 true PL2475645T3 (pl) | 2013-12-31 |
Family
ID=42830122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10749873T PL2475645T3 (pl) | 2009-09-11 | 2010-09-08 | 5-(3,4-dichlorofenylo)-n-(2-hydroksycykloheksylo)-6-(2,2,2- trifluoroetoksy)nikotynoamid i jego sole jako środki zwiększające poziom cholesterolu hdl |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8227491B2 (OSRAM) |
| EP (1) | EP2475645B1 (OSRAM) |
| JP (1) | JP5604520B2 (OSRAM) |
| KR (1) | KR101382871B1 (OSRAM) |
| CN (1) | CN102639506B (OSRAM) |
| AR (2) | AR078352A1 (OSRAM) |
| AU (1) | AU2010294277B2 (OSRAM) |
| BR (1) | BR112012005511B8 (OSRAM) |
| CA (1) | CA2771493C (OSRAM) |
| CL (1) | CL2012000611A1 (OSRAM) |
| CO (1) | CO6491033A2 (OSRAM) |
| CR (1) | CR20120089A (OSRAM) |
| CY (1) | CY1114377T1 (OSRAM) |
| DK (1) | DK2475645T3 (OSRAM) |
| EC (1) | ECSP12011723A (OSRAM) |
| ES (1) | ES2423821T3 (OSRAM) |
| HR (1) | HRP20130869T1 (OSRAM) |
| IL (1) | IL217920A (OSRAM) |
| IN (1) | IN2012DN00763A (OSRAM) |
| MA (1) | MA33563B1 (OSRAM) |
| MX (1) | MX2012002254A (OSRAM) |
| MY (1) | MY161103A (OSRAM) |
| NZ (1) | NZ597514A (OSRAM) |
| PE (1) | PE20120863A1 (OSRAM) |
| PL (1) | PL2475645T3 (OSRAM) |
| PT (1) | PT2475645E (OSRAM) |
| RS (1) | RS52987B (OSRAM) |
| RU (1) | RU2541475C2 (OSRAM) |
| SG (1) | SG179035A1 (OSRAM) |
| SI (1) | SI2475645T1 (OSRAM) |
| TW (1) | TWI412363B (OSRAM) |
| UA (1) | UA107088C2 (OSRAM) |
| WO (1) | WO2011029827A1 (OSRAM) |
| ZA (1) | ZA201201599B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US20120101282A1 (en) * | 2010-10-22 | 2012-04-26 | Pascal Dott | Process for the preparation of nicotinamide derivatives |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| WO2014180741A1 (en) * | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| US11814354B2 (en) | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| BRPI0609685A2 (pt) | 2005-04-06 | 2010-04-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos |
| RU2454405C2 (ru) * | 2006-10-04 | 2012-06-27 | Ф.Хоффманн-Ля Рош Аг | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина |
-
2010
- 2010-08-09 UA UAA201204339A patent/UA107088C2/ru unknown
- 2010-09-03 US US12/875,196 patent/US8227491B2/en active Active
- 2010-09-08 DK DK10749873.5T patent/DK2475645T3/da active
- 2010-09-08 MY MYPI2012001104A patent/MY161103A/en unknown
- 2010-09-08 SG SG2012016127A patent/SG179035A1/en unknown
- 2010-09-08 MX MX2012002254A patent/MX2012002254A/es active IP Right Grant
- 2010-09-08 CA CA2771493A patent/CA2771493C/en active Active
- 2010-09-08 BR BR112012005511A patent/BR112012005511B8/pt active IP Right Grant
- 2010-09-08 NZ NZ597514A patent/NZ597514A/xx unknown
- 2010-09-08 SI SI201030327T patent/SI2475645T1/sl unknown
- 2010-09-08 TW TW099130367A patent/TWI412363B/zh active
- 2010-09-08 ES ES10749873T patent/ES2423821T3/es active Active
- 2010-09-08 RU RU2012113924/04A patent/RU2541475C2/ru active
- 2010-09-08 PT PT107498735T patent/PT2475645E/pt unknown
- 2010-09-08 RS RS20130395A patent/RS52987B/sr unknown
- 2010-09-08 AU AU2010294277A patent/AU2010294277B2/en active Active
- 2010-09-08 WO PCT/EP2010/063136 patent/WO2011029827A1/en not_active Ceased
- 2010-09-08 KR KR1020127008704A patent/KR101382871B1/ko active Active
- 2010-09-08 JP JP2012528344A patent/JP5604520B2/ja active Active
- 2010-09-08 PL PL10749873T patent/PL2475645T3/pl unknown
- 2010-09-08 EP EP10749873.5A patent/EP2475645B1/en active Active
- 2010-09-08 HR HRP20130869AT patent/HRP20130869T1/hr unknown
- 2010-09-08 IN IN763DEN2012 patent/IN2012DN00763A/en unknown
- 2010-09-08 CN CN201080039932.7A patent/CN102639506B/zh active Active
- 2010-09-08 PE PE2012000302A patent/PE20120863A1/es active IP Right Grant
- 2010-09-09 AR ARP100103303A patent/AR078352A1/es not_active Application Discontinuation
-
2012
- 2012-01-12 CO CO12004250A patent/CO6491033A2/es active IP Right Grant
- 2012-02-02 IL IL217920A patent/IL217920A/en active IP Right Grant
- 2012-02-21 CR CR20120089A patent/CR20120089A/es unknown
- 2012-03-02 ZA ZA2012/01599A patent/ZA201201599B/en unknown
- 2012-03-03 EC ECSP12011723 patent/ECSP12011723A/es unknown
- 2012-03-05 MA MA34662A patent/MA33563B1/fr unknown
- 2012-03-08 CL CL2012000611A patent/CL2012000611A1/es unknown
-
2013
- 2013-09-05 CY CY20131100768T patent/CY1114377T1/el unknown
-
2018
- 2018-11-16 AR ARP180103371A patent/AR114032A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
| EP2360155A4 (en) | 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT | |
| ZA201201599B (en) | 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nico tinamide and salts thereof as hdl cholesterol raising agents | |
| IL197577A0 (en) | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents | |
| IL204663A0 (en) | Nicotinamide derivatives, preparastion thereof and therapeutic use thereof | |
| ZA200808191B (en) | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | |
| SG10201604819TA (en) | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | |
| IL220571A (en) | Compounds of 3 - (3-phenyl-imidazo [5,4- b] pyridinyl) -2-conjugated aminopyridine and pharmaceutical preparations containing them | |
| IL217774B (en) | Preparations for the treatment of Gaucher's disease and their uses | |
| PT2493306E (pt) | Composição herbicida sinergistica coontendo fluroxipir e cihalofop | |
| IL211566A0 (en) | 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases | |
| SI2252300T1 (sl) | Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze | |
| ZA200901132B (en) | Human GLP-1 mimetibodies, compositions, methods and uses | |
| IL187302A0 (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| IL201537A0 (en) | Heteroaryl substituted pyarzole derivatives useful for treating hyper- proliferative disorders and diseases associated with angiogenesis | |
| SG10201401415QA (en) | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | |
| BRPI1015967A2 (pt) | "unidade de dobradiça, e, peça de mobília." | |
| IL192907A0 (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| IL210937A (en) | New phenyl – amino isonicotinamide compounds and their use | |
| EP2268281A4 (en) | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | |
| SG10201609184PA (en) | Compositions and methods for extended therapy with aminopyridines | |
| IL200780A0 (en) | Pyridine and pyrimidine derivatives as mglur2 antagonists | |
| IL215483A0 (en) | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide | |
| IL220586A (en) | Carboxamide compound, a pharmaceutical composition containing it and its use | |
| EP2111400A4 (en) | Pyridine compounds and their use as P2Y12 antagonists |